PDCD1 and melanoma: Consistent with our previous study, we also found that Tim-3 downregulated after a decrease in the proportion of TGF-β secretion after PD-1 pathway blockade both in PBMCs and melanoma tissues, reflecting the excellent efficacy of anti-PD-1 therapy (Figures S2A–D).